The biotechnology company Novavax now plans to apply for emergency use authorization of its Covid-19 vaccine in the US in the third quarter of this year, CEO Stanley Erck told CNN in a phone interview on Monday. The American biotech firm previously announced plans to apply in the second quarter, but a delay in getting manufacturing data involving quality, consistency, and stability tests for manufacturing and storage of vaccine has pushed back the timeline, Erck said.